PROCEEDINGS VOLUME 3909
BIOS 2000 THE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL OPTICS | 22-28 JANUARY 2000
Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy IX
IN THIS VOLUME

0 Sessions, 20 Papers, 0 Presentations
Clinical PDT  (4)
BIOS 2000 THE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL OPTICS
22-28 January 2000
San Jose, CA, United States
Clinical PDT
Proc. SPIE 3909, Intraperitoneal photodynamic therapy for peritoneal carcinomatosis and sarcomatosis, 0000 (29 March 2000); doi: 10.1117/12.379893
Proc. SPIE 3909, Clinical trials of photodynamic therapy of malignant brain tumors, 0000 (29 March 2000); doi: 10.1117/12.379894
Proc. SPIE 3909, Low-dose Photofrin-induced PDT offers excellent clinical response with minimal morbidity in chest wall recurrence of breast cancer, 0000 (29 March 2000); doi: 10.1117/12.379895
Proc. SPIE 3909, Preliminary clinical data on a new photodynamic therapy photosensitizer: 2-[1-hexyloxyethyl]-2-devinylpyropheophorbide-a (HPPH) for treatment of obstructive esophageal cancer, 0000 (29 March 2000); doi: 10.1117/12.379876
Preclinical PDT
Proc. SPIE 3909, Photoimmunotherapy of ovarian cancer (Invited Paper), 0000 (29 March 2000); doi: 10.1117/12.659975
Proc. SPIE 3909, Photodynamic pathogen inactivation in red cell concentrates with the silicon phthalocyanine Pc 4, 0000 (29 March 2000); doi: 10.1117/12.379877
Proc. SPIE 3909, Motexafin lutetium in graft coronary artery disease, 0000 (29 March 2000); doi: 10.1117/12.379878
Proc. SPIE 3909, Photofrin mediated PDT in normal rat brain: assessment on apoptosis as a quantitative biological endpoint, 0000 (29 March 2000); doi: 10.1117/12.379879
Proc. SPIE 3909, Intracellular PDT activity of a pegylated form of meso-tetra-(hydroxy-phenyl)-chlorin (mTHPC), 0000 (29 March 2000); doi: 10.1117/12.379880
Proc. SPIE 3909, Multiphoton excitation and photodynamic activity of macromolecular derivatized mTHPC, 0000 (29 March 2000); doi: 10.1117/12.379882
Proc. SPIE 3909, Multitasking optical fiber probes for fluence-rate and fluorescent drug monitoring in vivo, 0000 (29 March 2000); doi: 10.1117/12.379883
PDT Mechanisms
Proc. SPIE 3909, Determinants of PDT-induced apoptosis, 0000 (29 March 2000); doi: 10.1117/12.379884
Proc. SPIE 3909, Photobleaching of photosensitizers applied for photodynamic therapy, 0000 (29 March 2000); doi: 10.1117/12.379885
Proc. SPIE 3909, Progress in development of an imaging system for fluorescence detection of GI tract cancers, 0000 (29 March 2000); doi: 10.1117/12.379886
Proc. SPIE 3909, Comparison of PDT efficiencies for photo-oxidation of substrate (NADPH) using a photosensitizer (Photofrin II), 0000 (29 March 2000); doi: 10.1117/12.379887
Poster Session
Proc. SPIE 3909, ALA-based photodynamic therapy in epithelial tumors: in vivo and in vitro models, 0000 (29 March 2000); doi: 10.1117/12.379888
Proc. SPIE 3909, Novel drug form of chlorin e6, 0000 (29 March 2000); doi: 10.1117/12.379889
Proc. SPIE 3909, One more PDT application of chlorin e6, 0000 (29 March 2000); doi: 10.1117/12.379890
Proc. SPIE 3909, First experience of photodithazine clinical application for photodynamic therapy of malignant tumors, 0000 (29 March 2000); doi: 10.1117/12.379891
PDT Mechanisms
Proc. SPIE 3909, Modeling the oxygen microheterogeneity of tumors for photodynamic therapy dosimetry, 0000 (29 March 2000); doi: 10.1117/12.379892
Back to Top